Novel Drug for Menopause Symptoms Passes Phase 3 Test Novel Drug for Menopause Symptoms Passes Phase 3 Test

The novel NK3 receptor inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news